Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT
Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
Patients with relapsed medulloblastoma, ependymoma and ATRT have a very poor prognosis
whether treated with conventional chemotherapy, high-dose chemotherapy with stem cell rescue,
irradiation or combinations of these modalities. Antiangiogenetic therapy has emerged as new
treatment option in solid malignancies. The frequent, metronomic schedule targets both
proliferating tumor cells and endothelial cells, and minimizes toxicity. In this study the
investigators will evaluate the use of biweekly intravenous bevacizumab in combination with
five oral drugs (thalidomide, celecoxib, fenofibrate, and alternating cycles of daily
low-dose oral etoposide and cyclophosphamide), augmented with alternating courses of
intrathecal etoposide and cytarabine. The aim of the study is to extend therapy options for
children with recurrent or progressive medulloblastoma, ependymoma and ATRT, for whom no
known curative therapy exists, by prolonging survival while maintaining good quality of life.
The primary objective of the MEMMAT trial is to evaluate the activity of this multidrug
antiangiogenic approach in these heavily pretreated children and young adults. Additionally,
progression-free survival (PFS), overall survival (OS), as well as feasibility and toxicity
will be examined.